Cancer Treatment Market Size, Top Share, Demand To 2034

(MENAFN- Straits Research) Introduction

The market growth is attributed to the rising burden of cancer worldwide, expanding therapeutic innovations, rapid approval and adoption of novel therapies and improved access to precision diagnostics.

The global cancer treatment market size was estimated at USD 282.28 billion in 2025 and is anticipated to grow till USD 643.50 billion in 2034 at a CAGR of 9.63% from 2026-2034.

Market Dynamics Investment in private and public research and development drives the market growth

There exists a persistent unmet demand in Oncology attributable to the rising incidence of cancer diagnoses. This draws cash inflows from both private investors and the government. Pharmaceutical conglomerates are expediting their pipelines via strategic acquisitions, while the government significantly invests in infrastructure and early-stage scientific research.

• In July 2025, Merck KGaA finalised the acquisition of SpringWorks Therapeutics, a biopharmaceutical firm specialising in severe rare diseases and cancer, for USD 3.4 billion.

This dual approach mitigates development risks and accelerates commercialisation timelines, hence ensuring continuous market growth.

Better testing that matches patients to the right cancer drugs

Hospitals now use simpler, faster tests on tumors and blood to find who will benefit from which medicine. When these tests spot the right signal or gene change, doctors can start the most effective drug sooner, often in earlier stages. Health systems are covering these tests more often, and regulators approve new drugs together with their tests, which speeds real-world use. This means more patients qualify, start treatment earlier, and stay on therapy longer, lifting demand for checkpoint drugs, targeted pills, antibody drug conjugates, and even cell and gene therapies across the cancer treatment market.

Key Highlights

• By Cancer Type , the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, hematologic malignancies, pancreatic cancer, ovarian cancer, and others. The prostate cancer segment is estimated to grow at a CAGR of 17% in 2025.
• By Product Type , cytotoxic chemotherapies, monoclonal antibodies, immuno-oncology checkpoint inhibitors, antibody-drug conjugates, cell & gene therapies, and others. The immuno-oncology checkpoint inhibitors segment dominated the market with a revenue share of 28% in 2025.
• By End-User , the market is segmented into hospitals and cancer centers, research and academic centers, and others. Research and academic centers segment is estimated to grow at a CAGR of 9.8%.
• Asia Pacific is emerging as the fastest-growing region in cancer treatment, exhibiting a CAGR of 10.2% from 2026 to 2034. This growth is attributed to rising incidence, increasing national health budgets, growing local R&D capacity, and rapid scaling of diagnostics and hospital infrastructure.

Competitive Players

The key players in the global market are Roche Holding AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Co., AstraZeneca PLC, Eli Lilly & Co., Johnson & Johnson, Amgen Inc., Sanofi, Takeda Pharmaceutical Co., Bayer AG, Astellas Pharma Inc., Ipsen, BeiGene Ltd., EsoBiotec, Zai Lab Ltd., and others.

Recent Developments

• In June 2025, McKesson Corporation completed its acquisition of a controlling interest in Community Oncology Revitalisation Enterprise Ventures, LLC (Core Ventures), for approximately $2.49 billion. The acquisition is intended to accelerate clinical development and expand access to cancer care.
• In February 2025, Novartis announced its acquisition of Anthos Therapeutics for up to $3.1 billion, including a $925 million upfront payment. The deal strengthens Novartis's cardiovascular portfolio with a drug that is also being developed for cancer-associated thrombosis.

Segmentation

By Cancer Type

Breast Cancer

Lung Cancer

Colorectal Cancer

Prostate Cancer

Hematologic malignancies

Pancreatic Cancer

Ovarian Cancer

Others

By Product Type

Cytotoxic chemotherapies

Monoclonal antibodies

Immuno-oncology checkpoint inhibitors

Antibody-drug conjugates

Cell & gene therapies

Others

By End-User

Hospitals and cancer centers

Research and academic centers

Others

By Region

North America

Europe

Asia Pacific

Latin America

The Middle East and Africa

Want to see full report on
Cancer Treatment Market Full Report

MENAFN05092025004597010339ID1110020861